GA-UNIBLOC-PUMP
8.9.2021 13:17:10 CEST | Business Wire | Press release
Unibloc Pump , a 37-year leader in the manufacture of positive displacement pumps, strainers, valves, bubble traps, and other solutions for sanitary flow control applications, today announced the acquisition of Flotronic Pumps , a UK-based manufacturer of specialized, air operated double diaphragm (AODD) pumps, and associated accessories. Founded in 1990, Flotronic Pumps has a global reputation as the inventor of the ‘One Nut’ AODD pump. Flotronic Pumps’ pioneering single bolt design significantly reduces process downtime by simplifying pump assembly / disassembly, providing savings in maintenance costs along with best-in-class air pump performance. Flotronic Pumps serves more than 1,000 global companies operating manufacturing facilities of iconic brands in food and beverage, consumer product goods, cosmetics, pharmaceuticals, and other critical process manufacturing applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005041/en/
Terms of the agreement were not disclosed. Flotronic Pumps will be solely owned by US-based Unibloc Pump while retaining its name, Flotronic Pumps Ltd. Joining the leadership team at Flotronic Pumps as chief executive officer will be Chris Stevens, the CEO of Unibloc Pump. Stevens will provide commercial leadership with strengths in business-to-business marketing, channel management, sales, and overall business management.
“This acquisition is a perfect hand-in-glove fit for Unibloc Pump.” Stevens said. “Unibloc Pump and Flotronic Pumps are ready to drive accelerated growth by offering customers products and solutions fueled by our passions for innovation, safety, and simplicity in maintenance to avoid downtime and increase efficiencies,” Stevens added.
Through the leadership of owner Stuart Whitehouse and the deep expertise of Director of Sales Leighton Jones, Flotronic Pumps has witnessed significant growth in Europe, as well as North America. “What we really like most of all about joining the Unibloc Pump family is that we share many of the same cultural values of simplicity in product design, quality in products, unabashed customer-focus, deep industry expertise, and a penchant for strong innovation,” said Jones. “These qualities will ensure that Unibloc Pump and Flotronic Pumps will be successful moving forward by flourishing through common bonds,” added Jones.
“Important to this acquisition is that both companies share complementary market footprints,” commented Whitehouse. “The combination will enable Unibloc Pump to grow its UK and European business, while also giving Flotronic Pumps an unmatched North American foothold. That should pay off in greater market coverage and increased overall value delivered to the customer,” Whitehouse added.
Unibloc Pump seeks to expand its vision to build a global sanitary flow control platform that delivers operational excellence, while targeting highly regulated hygienic end market applications, such as food and beverage, meat and poultry, and pharmaceutical processing. Unibloc Pump’s investment in Flotronic Pumps will provide resources to allow both companies to continue to grow and strengthen their global businesses.
The acquisition will allow Flotronic Pumps to leverage Unibloc Pump’s operational, manufacturing, sales, and distribution capabilities in North America out of its Kennesaw, GA facility. Likewise, Unibloc Pump will utilize Flotronic Pumps’ operations, manufacturing, sales, and distribution footprint in the United Kingdom and other European markets to further complement Unibloc’s existing European operation, Unibloc-R&H GmbH , based in Beckum, Germany.
Unibloc Pump is a portfolio company of May River Capital, a Chicago-based private equity firm devoted to helping high-caliber, lower middle-market industrial businesses grow and thrive. May River Capital takes pride in its unique approach and track record of building businesses through long-term partnership and collaboration. Its leadership team has broad experience helping promising companies become successful mid-size industrial businesses.
ABOUT UNIBLOC PUMP
Since 1984, Unibloc Pump has provided manufacturers in the food and beverage, pharmaceutical, bakery and confection, meat and poultry, brewery, and transportation industries with precision-engineered sanitary pumps, strainers, valves, bubble traps, and other accessory products to tackle the toughest sanitary jobs. Unibloc Pump is the premier designer of efficient, easy-to-clean pumps that help customers fight downtime, achieve a lower cost of operation, and meet deadlines with confidence. For more information, please visit www.uniblocpump.com .
ABOUT FLOTRONIC PUMPS
Based in West Sussex, United Kingdom and founded in 1990, Flotronic Pumps is a manufacturer of specialized AODD pumps and associated accessories. Flotronic’s products take performance far beyond traditional style AODD pump technology with a distinctive single bolt design that allows for in-line assembly / disassembly to be accomplished quickly and efficiently, significantly reducing process downtime, while providing best-in-class performance. For more information, please visit www.flotronicpumps.com .
ABOUT MAY RIVER CAPITAL
May River Capital is a Chicago-based private equity firm focused on investing in lower middle-market, industrial growth companies. May River Capital invests in high-quality industrial growth businesses, including precision manufacturing, engineered products and instrumentation, specialized industrial services, and value-added industrial distribution services. For more information, please visit www.mayrivercapital.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom